The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 58 | — | 20.1x | Near average | |
Growth | 54 | — | 5.6% | Near average | |
Quality | 17 | -42.4% | 7.6% | Below average | |
Safety | 53 | 0.9x | 0.4x | Near average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Enliven Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Enliven Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
The average price target for ELVN saw a slight decline of 3.6% over the past 30 days, dropping from 67 to 69.5 dollars, despite the number of analysts remaining steady at 3. This adjustment reflects technical caution in short-term valuations, with a notable Analyst Dispersion ranging between 59 and 80 dollars, indicating a variance in estimating the growth speed of the company's drug pipeline.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.